Significance of oncocytic features in poorly differentiated thyroid carcinoma - a bi-institutional experience

被引:8
作者
Xu, Bin [1 ]
Lubin, Daniel J. [2 ,3 ]
Dogan, Snjezana [1 ]
Ghossein, Ronald A. [1 ]
Viswanathan, Kartik [2 ,3 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA
[2] Emory Univ Hosp Midtown, Dept Pathol & Lab Med, Div Head & Neck Pathol & Cytopathol, 550 Peachtree St, Atlanta, GA 30309 USA
[3] Emory Univ, Winship Canc Inst, Decatur, GA 30322 USA
基金
美国国家卫生研究院;
关键词
Poorly differentiated; Thyroid carcinoma; Oncocytic; Outcomes; Molecular; TURIN PROPOSAL; HURTHLE; DRIVERS; REVEALS;
D O I
10.1007/s00428-022-03422-4
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Poorly differentiated thyroid carcinoma (PDTC), defined by Turin criteria, comprises a subset of high-grade follicular-derived thyroid carcinomas with intermediate prognosis. While differentiated oncocytic thyroid carcinomas demonstrate clinicopathologic and genetic differences compared to their non-oncocytic counterparts, similar data is limited in oncocytic (Hurthle) PDTCs (OPDTCs). Here, we assessed the impact of various oncocytic cut-offs in PDTCs on clinical, histologic and survival parameters. Our bi-institutional cohort comprised 210 primary PDTCs with available slides reviewed by at least one pathologist. Histologic features, including oncocytic fraction, were recorded. Clinicopathologic data were obtained, including overall survival (OS), disease-free survival (DFS), disease-specific survival (DSS), locoregional recurrence free survival (LRRFS), and distant metastasis-free survival (DMFS). Radioactive iodine avidity data was available for 125 PDTCs based on postoperative whole-body scanning. Within our cohort, 39.0% PDTCs had any oncocytic component with 24.8% meeting the 75% World Health Organization (WHO) oncocytic definition. Any oncocytic component and > 25% oncocytic cut-off correlated with decreased DSS and LRRFS, respectively, compared to non-oncocytic PDTCs (NOPDTCs) on univariate and multivariate analysis. The 100% oncocytic cut-off was significant for DSS on univariate analysis but a non-significant trend on multivariate analysis. Any oncocytic cut-off (100%, > 75%, > 50%, > 25%, or > 0%) conferred higher radioactive iodine (RAI)-refractoriness to OPDTCs compared to NOPDTCs. NF1 and PTEN alterations were enriched in OPDTCs (40% vs. 0%, and 60% vs 8%, respectively), whereas NRAS mutations were frequent in NOPDTCs (47% vs. 7%). Among PDTCs, the presence of oncocytes led to downward trend in all outcome parameters, especially for DSS and LRRFS. OPDTCs were enriched in NF1 and PTEN mutations. Consistently, all oncocytic cut-offs were associated with RAI-refractoriness. Accordingly, additional studies are needed to reassess the current 75% cut-off used to define oncocytic thyroid lesions.
引用
收藏
页码:479 / 491
页数:13
相关论文
共 22 条
  • [1] Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression
    Asioli, Sofia
    Erickson, Lori A.
    Righi, Alberto
    Jin, Long
    Volante, Marco
    Jenkins, Sarah
    Papotti, Mauro
    Bussolati, Gianni
    Lloyd, Ricardo V.
    [J]. MODERN PATHOLOGY, 2010, 23 (09) : 1269 - 1278
  • [2] Poorly Differentiated Oncocytic (Hurthle Cell) Follicular Carcinoma: an Institutional Experience
    Bai, Shuting
    Baloch, Zubair W.
    Samulski, Teresa D.
    Montone, Kathleen T.
    LiVolsi, Virginia A.
    [J]. ENDOCRINE PATHOLOGY, 2015, 26 (02) : 164 - 169
  • [3] Overview of the 2022 WHO Classification of Thyroid Neoplasms
    Baloch, Zubair W.
    Asa, Sylvia L.
    Barletta, Justine A.
    Ghossein, Ronald A.
    Juhlin, C. Christofer
    Jung, Chan Kwon
    LiVolsi, Virginia A.
    Papotti, Mauro G.
    Sobrinho-Simoes, Manuel
    Tallini, Giovanni
    Mete, Ozgur
    [J]. ENDOCRINE PATHOLOGY, 2022, 33 (01) : 27 - 63
  • [4] 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer American Thyroid Association Anaplastic Thyroid Cancer Guidelines Task Force
    Bible, Keith C.
    Kebebew, Electron
    Brierley, James
    Brito, Juan P.
    Cabanillas, Maria E.
    Clark, Thomas J., Jr.
    Di Cristofano, Antonio
    Foote, Robert
    Giordano, Thomas
    Kasperbauer, Jan
    Newbold, Kate
    Nikiforov, Yuri E.
    Randolph, Gregory
    Rosenthal, M. Sara
    Sawka, Anna M.
    Shah, Manisha
    Shaha, Ashok
    Smallridge, Robert
    Wong-Clark, Carol K.
    [J]. THYROID, 2021, 31 (03) : 337 - 386
  • [5] Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
    Cheng, Donavan T.
    Mitchell, Talia N.
    Zehir, Ahmet
    Shah, Ronak H.
    Benayed, Ryma
    Syed, Aijazuddin
    Chandramohan, Raghu
    Liu, Zhen Yu
    Won, Helen H.
    Scott, Sasinya N.
    Brannon, A. Rose
    O'Reilly, Catherine
    Sadowska, Justyna
    Casanova, Jacklyn
    Yannes, Angela
    Hechtman, Jaclyn F.
    Yao, Jinjuan
    Song, Wei
    Ross, Dara S.
    Oultache, Alifya
    Dogan, Snjezana
    Borsu, Laetitia
    Hameed, Meera
    Nafa, Khedoudja
    Arcila, Maria E.
    Ladanyi, Marc
    Berger, Michael F.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (03) : 251 - 264
  • [6] Poorly differentiated oncocytic thyroid carcinoma - diagnostic implications and outcome
    Dettmer, Matthias
    Schmitt, Anja
    Steinert, Hans
    Moch, Holger
    Komminoth, Paul
    Perren, Aurel
    [J]. HISTOPATHOLOGY, 2012, 60 (07) : 1045 - 1051
  • [7] Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
    Dong, Yiyu
    Gong, Yongxing
    Kuo, Fengshen
    Makarov, Vladimir
    Reznik, Ed
    Nanjangud, Gouri J.
    Aras, Omer
    Zhao, Huiyong
    Qu, Rui
    Fagin, James A.
    Sherman, Eric J.
    Xu, Bin
    Ghossein, Ronald
    Chan, Timothy A.
    Ganly, Ian
    [J]. MOLECULAR CANCER THERAPEUTICS, 2022, 21 (02) : 382 - 394
  • [8] Short Review: Genomic Alterations in Hurthle Cell Carcinoma
    Ganly, Ian
    McFadden, David G.
    [J]. THYROID, 2019, 29 (04) : 471 - 479
  • [9] Integrated Genomic Analysis of Hurthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes
    Ganly, Ian
    Makarov, Vladimir
    Deraje, Shyamprasad
    Dong, YiYu
    Reznik, Ed
    Seshan, Venkatraman
    Nanjangud, Gouri
    Eng, Stephanie
    Bose, Promita
    Kuo, Fengshen
    Morris, Luc G. T.
    Landa, Inigo
    Albornoz, Pedro Blecua Carrillo
    Riaz, Nadeem
    Nikiforov, Yuri E.
    Patel, Kepal
    Umbricht, Christopher
    Zeiger, Martha
    Kebebew, Electron
    Sherman, Eric
    Ghossein, Ronald
    Fagin, James A.
    Chan, Timothy A.
    [J]. CANCER CELL, 2018, 34 (02) : 256 - +
  • [10] Genomic Dissection of Hurthle Cell Carcinoma Reveals a Unique Class of Thyroid Malignancy
    Ganly, Ian
    Ricarte Filho, Julio
    Eng, Stephanie
    Ghossein, Ronald
    Morris, Luc G. T.
    Liang, Yupu
    Socci, Nicholas
    Kannan, Kasthuri
    Mo, Qianxing
    Fagin, James A.
    Chan, Timothy A.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (05) : E962 - E972